About: Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma‐derived products

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma‐derived products Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma‐derived products
Creator	Li, H Brown, J Reynolds, R Buczynski, G Osheroff, W Pifat, D Remington, K Renfrow, H Trejo, S
Source	Medline; PMC
abstract	Background and Objectives Human plasma is the source of a wide variety of therapeutic proteins, yet it is also a potential source of viral contamination. Recent outbreaks of emergent viral pathogens, such as West Nile virus, and the use of live vaccinia virus as a vaccine have prompted a reassessment of the viral safety of plasma‐derived products. The purpose of this study was to evaluate the efficacy of current viral inactivation methods for West Nile and vaccinia viruses and to reassess the use of model viruses to predict inactivation of similar viral pathogens. Materials and Methods Virus‐spiked product intermediates were processed using a downscaled representation of various manufacturing procedures. Virus infectivity was measured before and after processing to determine virus inactivation. Results The results demonstrated effective inactivation of West Nile virus, vaccinia virus and a model virus, bovine viral diarrhoea virus, during pasteurization, solvent/detergent treatment and caprylate treatment. Caprylate provided rapid and effective inactivation of West Nile virus, vaccinia virus, duck hepatitis B virus and Sindbis virus. Inactivation of West Nile virus was similar to that of bovine viral diarrhoea virus. Conclusions This study demonstrates that procedures used to inactivate enveloped viruses in manufacturing processes can achieve inactivation of West Nile virus and vaccinia virus. In addition, the data support the use of model viruses to predict the inactivation of similar emergent viral pathogens.
has issue date	2004-07-16(xsd:dateTime)
bibo:doi	10.1111/j.1423-0410.2004.00530.x
bibo:pmid	15260817
has license	no-cc
sha1sum (hex)	1a7e5568684ee44dfd3d6ac01ac6ccbf6f73806b
schema:url	https://doi.org/10.1111/j.1423-0410.2004.00530.x
resource representing a document's title	Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma‐derived products
has PubMed Central identifier	PMC7169325
has PubMed identifier	15260817
schema:publication	Vox Sang
resource representing a document's body	covid:1a7e5568684ee44dfd3d6ac01ac6ccbf6f73806b#body_text
is schema:about of	named entity 'plasma' named entity 'viral' named entity 'predict' named entity 'vaccine' named entity 'potential' named entity 'efficacy' named entity 'viral pathogens' named entity 'cholate' named entity 'WNV' named entity 'albumin' named entity 'product sample' named entity 'pasteurization' named entity 'plasma' named entity 'albumin' named entity 'HCV' named entity 'WNV' named entity 'Pasteurization' named entity 'WNV' named entity 'citrate' named entity 'citrate' named entity 'cholate' named entity 'WNV' named entity 'virus' named entity 'pathogen' named entity 'pathogen' named entity 'albumin' named entity 'virus' named entity 'Immunization' named entity 'cholate' named entity 'cholate' named entity 'West Nile virus' named entity 'sucrose' named entity 'virus' named entity 'cytotoxicity' named entity 'virus' named entity 'BVDV' named entity 'sheep' named entity 'WNV' named entity 'Caprylate' named entity 'Tween 80' named entity 'blood products' named entity 'FDA' named entity 'monoclonal antibody' named entity 'factor VIII' named entity 'hepatocytes' named entity 'tick' named entity 'caprylate' named entity 'physicochemical properties' named entity 'Hepadnavirus' named entity 'WNV' named entity 'vaccine' named entity 'pH 4' named entity 'WNV' named entity 'human immunodeficiency virus' named entity 'kidney' named entity 'cholate' named entity 'viruses' named entity 'albumin' named entity 'SARS' named entity '28 days' named entity 'WNV' named entity 'Sindbis' named entity 'yellow fever virus' named entity 'viruses' named entity 'infection' named entity 'HIV' named entity 'albumin' named entity 'viruses' named entity 'cholate' named entity 'detergent' named entity 'BVDV' named entity 'IVIG' named entity 'BVDV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software